Yes but only accepted for publication with revisions on 18th August
Safety study in humans confirmed
Efficacy in animal confirmed
It looks like some posters may have missed an important point in the announcement today
The study, conducted at The Scripps Research Institute in the US, showed that VIRALEZE™ administered nasally significantly reduced viral load by more than 99.9% in the lungs and trachea of animals challenged with SARS-CoV-2, compared with the virus levels in control animals. Animal challenge models of SARS-CoV-2 provide an opportunity to investigate aspects of the pathogenesis of disease that are not easily, nor able to be, studied in humans.
Ann: VIRALEZE Protects Against SARS-CoV-2 in Challenge Model, page-13
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
